A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection

Journal of Translational Medicine
Carolina VelázquezMercedes Durán

Abstract

In the context of our Regional Program of Hereditary Cancer, individuals fulfilling the criteria are tested for germline mutations to subsequently establish the clinical management. Our standard diagnostic approach focuses on sequencing a few classic high-risk genes, a method that frequently renders uninformative genetic results. This study aims to examine the improved yield offered by an On-Demand panel. We designed an On-Demand panel for the analysis of 35-genes associated with inherited cancer susceptibility in a total of 128 cases of Hereditary Breast and Ovarian Cancer (HBOC) and Hereditary Nonpolyposis Colorectal Cancer (HNPCC). Eighteen deleterious mutations were detected, in both routinely (BRCA2, MLH1, MSH2, PMS2) and non-routinely (ATM, BLM, BRIP1, CHEK2, MUTYH) tested genes. The screening extended to 35 genes rendered by patients carrying several- up to 6-Variants of Unknown Significance (VUS). Moreover, we confirmed the splicing disruption at RNA level for a not previously reported BRIP1 splicing mutation. Using an On-Demand panel, we identified 18 pathogenic mutation carriers, seven of which would have gone unnoticed with traditional analysis. Our results reinforce the utility of NGS gene panels in the diagnostic r...Continue Reading

References

Aug 24, 2004·Oncogene·Rebecca NagyCharis Eng
Jan 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Judy E Garber, Kenneth Offit
Oct 4, 2005·Journal of Medical Genetics·D Baralle, M Baralle
Dec 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allison W KurianSylvia K Plevritis
Apr 13, 2012·Applied Immunohistochemistry & Molecular Morphology : AIMM·Henrik OkkelsHenrik Bygum Krarup
Apr 16, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allison W KurianJames M Ford
Dec 4, 2014·Cancer Treatment Reviews·P EconomopoulouA Psyrri
Feb 13, 2016·Familial Cancer·Jessica StollKristen J Vogel Postula
Mar 16, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nadine TungJudy E Garber
Mar 31, 2016·Journal of the American Medical Informatics Association : JAMIA·Jennifer HintzscheAik Choon Tan
May 20, 2016·International Journal of Cancer. Journal International Du Cancer·Aung Ko WinMark A Jenkins
Sep 13, 2016·International Journal of Cancer. Journal International Du Cancer·Cornelia KrausAndré Reis
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Paluch-ShimonUNKNOWN ESMO Guidelines Committee
Nov 16, 2017·OncoTargets and Therapy·Akihiro Ohmoto, Shinichi Yachida
Nov 23, 2017·Cold Spring Harbor Molecular Case Studies·Volkan Okur, Wendy K Chung
Apr 4, 2018·Cold Spring Harbor Molecular Case Studies·Anna SchuhJenny C Taylor
Oct 26, 2018·Trends in Cancer·Omar L KantidzeSergey V Razin
Oct 30, 2018·Nucleic Acids Research·Philipp RentzschMartin Kircher
Mar 2, 2019·The Breast : Official Journal of the European Society of Mastology·Chrystelle ColasDominique Stoppa-Lyonnet
Mar 31, 2019·International Journal of Cancer. Journal International Du Cancer·Lídia FeliubadalóUNKNOWN Catalan Hereditary Cancer Group

❮ Previous
Next ❯

Citations

Oct 21, 2020·Genes, Chromosomes & Cancer·Steffen HirschChristian P Schaaf

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
PCR
electrophoresis

Software Mentioned

Ion Reporter
R
CADD
Clinvar
Human Splicing Finder ( HSF )
Ion

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.